TXG 10x Genomics: תחזית צמיחת רווחים לשנה הבאה

10x Genomics, Inc. (TXG) generates revenue through the sale of cell analysis systems and high-margin reagents, driving impressive growth. The profit growth rate model for the coming year visualizes these expectations, where the latest parameter is -7.30. However, success relies on research center grants, while business sustainability is guaranteed by a robust patent shield in the field of spatial biology.

This indicator measures the consensus forecast for the growth rate of net earnings per share, reflecting market expectations regarding future business profitability. By analyzing the analyst EPS growth estimates chart on GURU.Markets, an investor can see the potential for 10x Genomics, Inc. (TXG) to monetize its monopoly position in spatial genomics through the expansion of Chromium and Xenium systems and steady revenue from the sale of consumables.